The trial will evaluate the efficacy of Erbitux in combination with cisplatin and capecitabine chemotherapies as a first line treatment for patients with advanced/metastatic gastric adenocarcinoma, including gastroesophageal
Initial results from the collaboration showed positive results in using RXi’s proprietary self-delivering rxRNA (sd-rxRNA) compounds to silence genes up to 80% in hemopoietic cells. The companies said
Rivaroxaban is an oral direct Factor Xa inhibitor, which is being jointly developed by Bayer HealthCare and Johnson & Johnson Pharmaceutical Research & Development, LLC (J&JPRD). The submission
GOLD provides evidence-based guidelines for COPD management and is updated annually by a committee of leading COPD experts. A section on the new class, phosphodiesterase 4 (PDE4) inhibitors,
The trial is designed to assess the efficacy of TriRima administered twice daily as monotherapy in patients with treatment resistant depression. CeNeRx chief medical officer Daniel Burch said
StayinFront claims that StayinFront EdgeRx, a multi-lingual on-demand CRM with integrated analytic capabilities, offers flexibility to access the syatem online or offline featuring. Archimedes Pharma Global CIO Demi
Rituximab is a cancer (antineoplastic) medication which works by interfering with the growth of cancer cells by slowing their growth and spread in the body. Rituximab is also
The GORE C3 Delivery System allows physicians and interventionalists to reposition the Gore Excluder Device before the final release of the delivery catheter. The deployment control of the
The data from CVBT’s Phase II trial suggested that CVBT’s FGF-1 biological drug showed efficacy at a level greater than has been seen in any other treatments, for
As per the terms of the agreement, ImmunGene is entitled to get undisclosed fees which include upfront payment from Cephalon Australia a four-year option to leverage ImmunGene’s novel
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.